Patents Assigned to TG Therapeutics, Inc.
  • Anti-CD20 antibody compositions
    Patent number: 11965032
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: April 23, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Anti-CD20 antibody compositions
    Patent number: 11884740
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: January 30, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Anti-CD20 antibody compositions
    Patent number: 11814439
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 14, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes, Sri Hari Pandurang Miskin, Michael Weiss, Peter Sportelli
  • Anti-CD20 antibody compositions
    Patent number: 11807689
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 7, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
    Patent number: 10966977
    Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 6, 2021
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais du Fractionnement et das Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli
  • Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
    Patent number: 10729768
    Abstract: Highly effective combinations of a compound of formula A (a PI3K? selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K? and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 4, 2020
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K. V. S. Vakkalanka
  • COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS
    Publication number: 20190175592
    Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.
    Type: Application
    Filed: May 26, 2017
    Publication date: June 13, 2019
    Applicants: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Michael S. WEISS, Hari P. MISKIN, Peter SPORTLLI
  • Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
    Patent number: 9694071
    Abstract: Highly effective combinations of a compound of formula A (a PI3K? selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K? and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: July 4, 2017
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals NA, Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K. V. S. Vakkalanka